R-3750 is under clinical development by Rise Therapeutics and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how R-3750’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

R-3750 overview

R-3750 is under development for the treatment of ulcerative colitis and acute respiratory distress syndrome (ARDS). It is administered orally. The drug candidate is a pro-biotic based therapeutic. It is a is a genetically modified organism (GMO) and single strain comprised of Lactococcus (L.) lactis probiotic recombinantly expressing surface layer protein (SlpA). The drug candidate is developed based on TriPartite X (TPX) delivery platform technology

Rise Therapeutics overview

Rise Therapeutics is a biopharmaceutical company focused on developing targeted immunological-based biologics to treat immunology and inflammatory indications. Its pipeline product portfolio includes R-2487, an immunobiotic drug targeting key immunological pathway that induce specific populations of T regulatory cells to intervene with inflammatory processes; R-3750 is an immunobiotic program that induces immune homeostasis and enhancing the gut barrier for the treatment of gastrointestinal (GI) inflammatory disease. Its oral delivery platform, TriPartite X (TPX), is a novel DNA assembly approach that allows creation of recombinant probiotics to escort targeted protein therapies to the site of action, the intestinal space. Rise Therapeutics is headquartered in Rockville, Maryland, the US.

For a complete picture of R-3750’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.